肿瘤防治研究Issue(9)：1038-1041,4.DOI:10.3971/j.issn.1000-8578.2011.08.016
血清CA19-9、CEA、CA125动态变化在判断胰腺癌同期放化疗患者疗效及预后中的应用
CA19-9, CEA and CA125 as A Predictor for Response and Survival in Unresectable Pancreatic Cancer Patients Treated with Chemoradiotherapy
穆晓峰 1王迎选 1俞立权 1宁健 1曹京旭 1史铭 1付淑云 1宋薇 1李韧1
作者信息
摘要
Abstract
Objective To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) , carcinoem-bryonic antigen (CEA) and cancer antigen 125 (CA125) levels for predicting response and survival in un-respectable pancreatic cancer (UPC) treated with concurrent chemoradiotherapy. Methods We retrospectively reviewed data from 24 patients with UPC between 2004 and 2009. CA 19-9, CA125 and CEA levels (pre- , post-treatment and intra-treatment every week) and their decline were analyzed for radiolog-ic response and overall survival. Results Of all patients, response rate was 25%, the median survival time (MST) was 8. 4 months . Pretreatment CA 19-9≥1 000 u/ml (MST, 12 vs. 6 months; P = 0. 039), CA125≥50 u/ml(MST, 12 vs. 6 months; P=0. 04), were unfavorable prognostic factors. Post-treatment tumor marker (CA19-9 or CA125 or CEA) decline ≥50% (MST, 12 vs. 6. 0 months; P = 0. 005) was prognostic factors. Intra-treatment all patients were dived into "up-tendency" and "down-tendency" according to tumor marker (CA19-9 or CA125 or CEA) levels every week. MST was 6 months and 15 months and response rate was 0 and 50% in "up-tendency" and "down-tendency" group. Conclusion CA19-9, CEA and CA125 may possibly serve as a predictor for response and survival in unresectable pancreatic cancer patients treated with chemoradiotherapy.关键词
胰腺癌/同期放化疗/CEA/CA19-9/CA125Key words
Pancreatic cancer/ Concurrent chemoradiotherapy/ CEA/ CA19-9/ CA125分类
医药卫生引用本文复制引用
穆晓峰,王迎选,俞立权,宁健,曹京旭,史铭,付淑云,宋薇,李韧..血清CA19-9、CEA、CA125动态变化在判断胰腺癌同期放化疗患者疗效及预后中的应用[J].肿瘤防治研究,2011,(9):1038-1041,4.
